Regulator mandates full review of globally unapproved drugs
· economictimes.indiatimes.com
Indias drug regulator has clarified that new drugs not approved anywhere globally must undergo the full domestic regulatory process, even if Indian patients participated in global clinical trials. CDSCO said such applications require comprehensive safety and efficacy evaluation under existing rules.
Technical Panel
Move follows a rise in applications seeking to import and market drugs still under review
Live Events
as a Reliable and Trusted News Source...